BioMarin to Gain Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth Products with ...

Creating One of the Largest Omni-Channel Retailers Across the Full Inclusive Sizing Market, with Approximately $1.2 Billion of Combined Annual ...

THE NATION; In a thrilling display of intellect, eloquence, and youthful brilliance, 14-year-old Ndubuisi Praise of Community ...

STAAR Surgical Company , the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICLtm) for vision correction, today reported that independent industry analysts have ...

Positioning itself as "The Home of the Boy-child," Merishaw School opens its doors to families seeking a holistic educational ...

Lung development begins during embryogenesis and continues after birth. It includes branching of airways, formation of ...

Investing in leading growth stocks can lead to large gains. For more than a decade now, growth stocks have been the driving force behind the market's run higher. As long as the bull market lasts, that ...

The Vanguard Growth ETF has been a significant market beater. The Invesco QQQ Trust is heavily tech focused and can sometimes be volatile, but returns have been impressive. The Schwab U.S. Large-Cap ...

BioMarin Pharmaceutical Inc. and Amicus Therapeutics announced today that BioMarin has entered into a definitive agreement to acquire Amicus for $14.50 per share in an all-cash transaction for a total ...

Treasury Secretary Scott Bessent said he expects the U.S. to end the year with a better-than-expected 3% gross domestic product (GDP) growth. Bessent appeared Sunday on CBS News' "Face the Nation" and ...

Flora Growth Corp. (NASDAQ: FLGC) surged 5.98% to $10.55 in after-hours trading on Thursday. Check out the current price of FLGC stock here. According to Benzinga Pro data, the stock of the ...